Crossmark

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2024-010013

Published Online: 2025-01-16

Published Print: 2025-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Nelson, Blessie E https://orcid.org/0000-0002-8227-638X
O'Brien, Shaun

Sheth, Rahul A https://orcid.org/0000-0001-9615-8985
Hong, David S https://orcid.org/0000-0001-8721-1609
Naing, Aung https://orcid.org/0000-0002-4803-8513
Zhang, Xiaoping

Xu, Amy

Hamuro, Lora

Suryawanshi, Rasika

McKinley, Derrick

Novosiadly, Ruslan D

Piha-Paul, Sarina A https://orcid.org/0000-0001-9455-1660
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03444753 at ClinicalTrials.gov

Documents that mention this clinical trial

First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14584

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2024-010013

nct03444753 at ClinicalTrials.gov

Documents that mention this clinical trial

First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14584

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2024-010013

nct03444753 at ClinicalTrials.gov

Documents that mention this clinical trial

First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.e14584

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2024-010013
Funding

Funding for this research was provided by:

Bristol-Myers Squibb Co. (N/A)

Clinical Translational Science Award (1UL1 TR003167, UM1 TR0045906)

MD Anderson Cancer Center (NIH/NCI P30 CA016672)
License Information

License valid from 2025-01-16

Document is current

Any future updates will be listed below